Skip to Content
by Leigh MacMillan | Wednesday, Jun. 14, 2017, 8:00 AM
About 10 percent of patients with colorectal cancer express a mutated form of the signaling molecule BRAF, which may be targeted for treatment by selective BRAF inhibitors. PET (positron emission tomography) imaging using a standard glucose probe is not able to predict response to BRAF inhibitors.
In addition to becoming dependent on glucose, cancer cells exhibit increased dependency on the amino acid glutamine. H. Charles Manning, Ph.D., and colleagues explored the use of a glutamine PET probe to predict response to mutant BRAF-targeted therapy in preclinical mouse models of colon cancer. They found that glutamine PET imaging predicted response to BRAF inhibition in tumors expressing mutant BRAF, but not in tumors expressing wild-type BRAF.
The findings, reported in the June issue of Molecular Imaging and Biology, demonstrate the utility of non-invasive PET imaging of glutamine uptake to predict response to BRAF-targeted therapy in colon cancer and could improve patient selection in colon cancer trials using BRAF-targeted therapies.
This research was supported by grants from the National Institutes of Health (CA140628, CA095103, DK058404, CA068485), the Kleberg Foundation, and the Vanderbilt Center for Molecular Probes.
Send suggestions for articles to highlight in Aliquots and any other feedback about the column to email@example.com
Leigh MacMillan, (615) 322-4747
Health and Medicine, Reporter, Research Aliquots, BRAF, H. Charles Manning, Kleberg Foundation, NCI, NIDDK, NIH, PET, PET imaging, radiology and radiological sciences, Reporter June 9 2017, targeted cancer therapy, Vanderbilt Center for Molecular Probes, Vanderbilt University Institute of Imaging Science
There are lots of ways to keep up with Vanderbilt. Choose your preferred method: